Education
About Us
Working with TipRanks
Follow Us
COSMO Pharmaceuticals N.V. (DE:C43)
FRANKFURT:C43
C43 Stock Chart & Stats
€97.50
-€1.00(-1.46%)
At close: 4:00 PM EST
€97.50
-€1.00(-1.46%)
Day’s Range― - ―
52-Week Range€48.60 - €141.00
Previous CloseN/A
Volume64.00
Average Volume (3M)48.00
Market Cap
CHF1.59B
Enterprise Value€1.48B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding17,543,522
10 Day Avg. Volume20
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF154.92Price Target Upside58.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.81
Revenue Forecast (FY)CHF140.25M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExceptionally low leverage and substantial equity provide durable financial flexibility. This backing allows the company to absorb operational swings, fund R&D or commercialization without immediate external financing, and maintain strategic optionality for partnerships or targeted investments over the medium term.
Specialized Gastroenterology FocusA clear, specialized focus on gastroenterology and endoscopy builds domain expertise, closer clinician relationships, and targeted product development. That specialization supports durable competitive positioning in a defined clinical niche where adoption curves and reimbursement credibility tend to persist over time.
Multiple Revenue StreamsA hybrid commercial/licensing model diversifies cash sources and reduces reliance on any single product. Licensing payments and royalties can provide non-dilutive funding and lump-sum support, while direct sales and distribution maintain commercial presence, improving medium-term resilience to product-level setbacks.
Bears Say
Earnings VolatilityLarge swings in profitability reduce visibility for investors and management, complicate long-term planning and resource allocation, and weaken credibility with partners. Persistent volatility suggests earnings are sensitive to episodic events, limiting confidence in sustainable margin recovery over the next several quarters.
Cash Flow DeteriorationA swing from large positive to negative operating and free cash flow materially reduces internal funding ability. That increases dependence on the balance sheet or partners for R&D and commercialization, tightening the company's margin of safety and potentially forcing trade-offs in investment or licensing strategies.
Sharp Recent Revenue DeclineA steep revenue drop undermines scale economics and raises questions about product sustainability, contract expiries or market share loss. Reduced top-line scale pressures margins and the returns on fixed commercial/R&D investments, making durable recovery and forecasting more uncertain.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €48.60 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.59B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 134 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -€0.02 earnings per share for the quarter, missing the consensus estimate of €0.2 by -€0.22.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.02 in its last earnings report, missing expectations of €0.2. Following the earnings report the stock price went down -9.483%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€154.92
▲(58.89% Upside)
Technical Analysis
Roche Holding AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
medmix AG
―
Medartis Holding AG
―
Options Prices
Currently, No data available
---